about
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.Emerging treatment approaches for myeloma-related bone disease.Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.Mechanisms of bone destruction in multiple myeloma.The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis.Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.Management of multiple myeloma bone disease: impact of treatment on renal functionLonger procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: reHow I treat elderly patients with plasma cell dyscrasiasToll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor ChopOptimizing therapy in bortezomib-exposed patients with multiple myelomaReal-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working groupDetection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathiesScreening for Gaucher disease among patients with plasma cell dyscrasiasEuropean myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasCorrection to: Current Approaches in the Management of Hepatic AdenomasConsolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesReal-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaPrimary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasoneVulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsElotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myelomaEffect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myelomaTreatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case reportEfficacy of lenalidomide as salvage therapy for patients with AL amyloidosisEvaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemiaEmerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone DiseaseMultiple myeloma: Role of autologous transplantationElevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WMCell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlationsBone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupAnti-BCMA antibodies in the future management of multiple myelomaPulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcomeA revised international prognostic score system for Waldenström's macroglobulinemia
P50
Q37397495-4008D685-F1DF-42A6-AF8A-D3505D694AF4Q38730723-D47AC479-B890-473F-AF84-34826A2E61BBQ39090721-FA3940C2-E4D8-41A4-AFA1-28FB12200BE0Q39776586-28470756-B775-4D55-894E-2166951DE115Q40261261-3A1D2897-8C78-4E76-A530-C65DEDCC4AEDQ41288885-B4F799EB-B993-4FF6-AFC9-CA8768D58439Q42910816-D069F530-FE43-4C5F-B47A-46FDCE7CDE08Q43759174-8BA444F8-AC4A-42AF-95AD-A703FB9CECF8Q47756922-3E7E7450-F7FF-4915-9E31-2B4F55CD221EQ48251592-DE7F9416-C894-4C79-9A06-DA8627E6D59BQ48907194-2B4174C0-2377-43B5-A22A-A91279E113B5Q49546522-F90836F9-B0C2-4C29-9EAF-93855DA2483FQ53173592-02A737D8-08DC-4CD9-B10F-CBC0B93B332AQ57026820-31B57C62-24B5-4A3B-A055-942BAF27EF2BQ58592860-2C395440-0B4F-42BA-96C5-93F7EF55653CQ60949296-FD851194-CED0-4A51-864A-1AB95AD22972Q64084639-09B758B4-B64A-4091-BDD4-C5C2633199CBQ88776020-D115A15D-7647-43CB-87A0-1E987EB17608Q89670899-F7BC20F6-D137-4FBC-8459-B1F2B079FDABQ90351128-3765653E-49BB-4024-B4B0-444FC9C67F3EQ90364038-88540E43-A65F-4FFF-A0B1-3C4F47336163Q90428497-EEE03521-FB58-4343-8C89-107BFA799D8FQ90645330-BA1B3DDB-BBB3-45D8-B215-07F260557DFDQ90787473-338BC2B1-51D0-4418-98F4-CBDE477FE6AAQ90821787-81E2BD23-DFEB-48BE-BED3-B89CA2767451Q90925215-F0AF409D-AF83-4818-A20A-7767F3D70F24Q90978221-F50A1C14-054D-4C45-9FC8-E612486B599DQ91074936-0FBDF20A-D2B8-4B28-A836-1374CE742FADQ91075615-34586175-4986-4C83-B146-1DEBAD83DBCEQ91125501-7B6631EB-6DCF-407E-93A6-27785FD55B74Q91136241-7DAD1EFD-BEF5-4460-A5C5-ADC7823D0487Q91153652-B9EFCF62-27D8-40A8-B8B1-B34A9D6C8BD6Q91306951-778D52E9-C698-4B9D-A66F-455F866C86D4Q91466132-85BA2635-448A-4170-83C1-7A17730F8D98Q91492419-CA1FEE01-A55B-4787-9FC7-BCF9FBFF5E5CQ91529274-6E4ABC43-7570-4B3D-923C-F6917D6DA2D8Q91658209-97666142-D2AF-4B41-A6E5-6FCB5D61C5EAQ91953616-E3400E3E-A39D-469F-9579-00D3B6BD2F1EQ92135856-07599F79-8B62-4B85-84CE-62284644B828Q92226928-3E818416-CB01-40BA-AC46-64FF76B4D3D4
P50
description
researcher
@en
name
Maria Gavriatopoulou
@en
type
label
Maria Gavriatopoulou
@en
prefLabel
Maria Gavriatopoulou
@en
P31
P496
0000-0002-6244-1229